The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TLIS, AFIB and MP

NEW YORK, NY / ACCESSWIRE / February 25, 2022 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Talis Biomedical Corporation TLIS
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Talis common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's February 2021 initial public offering.
Lead Plaintiff Deadline: March 8, 2022

According to the lawsuit, documents that the Company issued in connection with its IPO failed to disclose to investors: (1) that the comparator assay in the primary study lacked sufficient sensitivity to support Talis's Emergency Use Authorization application for Talis One COVID-19 test; (2) that, as a result, Talis was reasonably likely to experience delays in obtaining regulatory approval for the Talis One COVID-19 test; (3) that, as a result, the Company's commercialization timeline would be significantly delayed; and (4) that, as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in TLIS: https://www.kleinstocklaw.com/pslra-1/talis-biomedical-corporation-loss-submission-form?id=24073&from=1

Acutus Medical, Inc. AFIB
This lawsuit is on behalf of all purchasers of Acutus common stock between May 13, 2021 and November 11, 2021, inclusive.
Lead Plaintiff Deadline: April 18, 2022

The complaint alleges that throughout the class period Acutus Medical, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) a material percentage of the Company's AcQMap imaging and mapping systems under evaluation had been randomly installed at sites with little, if any, consideration given to whether the healthcare providers at the selected locations were likely to adopt, or desire, the Company's products; (b) a material percentage of the AcQMap systems under evaluation had been installed in locations where the Company did not possess the infrastructure necessary to appropriately educate, train, and support medical service providers on the system's operations; (c) as a result of (a) and (b) above, defendants were in the process of designing a strategic plan to terminate and relocate approximately 20% of then-existing AcQMap systems evaluation arrangements; (d) the Company's management discussion and analysis was materially false and misleading and failed to disclose that the termination and relocation of approximately 20% of existing AcQMap systems evaluation arrangements was reasonably likely to have a material adverse effect on the Company's 2021 financial results; and (e) the Company's risk factor discussions were materially false and misleading and made reference to potential risks without disclosing that such risks were then-existing or adequately describing the specific nature of the risks then facing the Company.

Learn about your recoverable losses in AFIB: https://www.kleinstocklaw.com/pslra-1/acutus-medical-inc-loss-submission-form?id=24073&from=1

MP Materials Corp. f/k/a Fortress Value Acquisition Corp. MP
Class Period: May 1, 2020 - February 2, 2022
Lead Plaintiff Deadline: April 25, 2022

The MP lawsuit alleges that throughout the class period, MP Materials Corp. f/k/a Fortress Value Acquisition Corp. made materially false and/or misleading statements and/or failed to disclose that: (i) Fortress Value Acquisition Corp. ("FVAC") had overstated its due diligence efforts and expertise with respect to identifying target companies to acquire; (ii) FVAC performed inadequate due diligence into Legacy MP Materials prior to the business combination, or else ignored significant red flags regarding, inter alia, Legacy MP Materials' management, compliance policies, and Mountain Pass's profitability; (iii) as a result, the Company's future business and financial prospects post-business combination were overstated; (iv) MP Materials engaged in an abusive transfer price manipulation scheme with a related party in the People's Republic of China to artificially inflate the Company's profits; (v) MP Materials' ore at the Mountain Pass Rare Earth Mine and Processing Facility was not economically viable to harvest for rare earth metals; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in MP: https://www.kleinstocklaw.com/pslra-1/mp-materials-corp-f-k-a-fortress-value-acquisition-corp-loss-submission-form?id=24073&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE : The Klein Law Firm